Catalog No.: PC-49868Not For Human Use, Lab Use Only.
Debio 0932 (CUDC-305, RGRN-305) is a highly potent, oral and BBB-penetrant HSP90 inhibitor, shows high affinity for HSP90alpha/beta and HSP90 complex derived from cancer cells with IC50 of 100 nM and 48.8 nM, respectively.
Debio 0932 (CUDC-305, RGRN-305) is a highly potent, oral and BBB-penetrant HSP90 inhibitor, shows high affinity for HSP90alpha/beta and HSP90 complex derived from cancer cells with IC50 of 100 nM and 48.8 nM, respectively.
Debio 0932 (CUDC-305) displays potent antiproliferative activity against a broad range of cancer cell lines with mean IC50 of 220 nM.
Debio 0932 (CUDC-305) exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.
Debio 0932 (CUDC-305) also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.
Debio 0932 (CUDC-305) binds strongly to HSP90 extracted from erlotinib-resistant NSCLC cells (IC50=70 nM).
Debio 0932 (CUDC-305) potently inhibits tumor growth in subcutaneous xenograft models of H1975 and A549, which harbor EGFR T790M mutation or K-ras mutations conferring acquired and primary erlotinib resistance, respectively.
